From Ambito · · 1m 10s
Argentina Joins Patent Treaty: Drug Prices and Future
Argentina joins global patent treaty, potentially lowering drug costs but raising competition concerns.
In brief
Argentina joins global patent treaty, potentially lowering drug costs but raising competition concerns. Argentina's adoption of the PCT patent treaty may reduce drug development costs but could delay generic medicines and increase prices. Originally reported by Ambito.
Senate approves Argentina's PCT adhesion
The Senate approved Argentina's joining the Patent Cooperation Treaty with 47 yes and 22 no votes after nearly three decades of debate.
PCT simplifies international patent processes
The treaty allows one international application for patents across multiple countries, replacing separate procedures in each jurisdiction.
Argentina retains national patent control

Argentina keeps the final decision on patents with the INPI, requiring local evaluation for medicines and other products.
Industry fears higher drug prices
Local pharmaceutical companies warn that stronger patent protection could delay generic medicines and increase consumer costs.
AmCham supports PCT benefits
The US Chamber of Commerce in Argentina says the treaty will reduce development costs and attract international investment.
Drug development costs estimated at $2.6bn
Developing a new drug can take 10-15 years and cost nearly 2.6 billion dollars, according to US Chamber of Commerce estimates.
The takeaway
Argentina's adoption of the PCT patent treaty may reduce drug development costs but could delay generic medicines and increase prices.
Read the TL;DR — this story on one card.





